BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
11/10/2014 7:09:00 PM | Browse: 1862 | Download: 1612
 |
Received |
|
2013-10-29 15:38 |
|
Peer-Review Started |
|
2013-10-30 20:30 |
 |
First Decision by Editorial Office Director |
|
|
|
Return for Revision |
|
2014-04-02 08:58 |
|
Revised |
|
2014-04-07 20:27 |
|
Publication Fee Transferred |
|
|
|
Second Decision by Editor |
|
2014-05-05 09:29 |
|
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2014-05-05 09:58 |
|
Articles in Press |
|
2014-05-23 10:09 |
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2014-10-25 13:59 |
|
Publish the Manuscript Online |
|
2014-11-10 19:10 |
| Category |
Oncology |
| Manuscript Type |
Topic Highlights |
| Article Title |
S-1 in the treatment of pancreatic cancer
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Kentaro Sudo, Kazuyoshi Nakamura and Taketo Yamaguchi |
| Funding Agency and Grant Number |
|
| Corresponding Author |
Kentaro Sudo, MD, PhD, Department of Gastroenterology, Chiba Cancer Center, 666-2 Nitona-cho, Chuo-ku, Chiba 260-8717, Japan. kentarosudo9@yahoo.co.jp |
| Key Words |
Pancreatic cancer; S-1; Chemotherapy; Randomized controlled trial; Chemoradiotherapy; Adjuvant therapy |
| Core Tip |
This review article focuses on clinical trials of S-1-based chemotherapy for advanced pancreatic cancer. Recently, S-1 has been demonstrated to be non-inferior to gemcitabine in overall survival for metastatic or locally advanced pancreatic cancer in a large-scale phase Ⅲ study (GEST study). Furthermore, S-1 has been shown to be superior to adjuvant chemotherapy with gemcitabine in overall survival in patients with resected pancreatic cancer in another phase Ⅲ study (JASPAC-01 study). In addition to gemcitabine, S-1 is now considered one of the key drugs in Japan. |
| Publish Date |
2014-11-10 19:10 |
| Citation |
Sudo K, Nakamura K, Yamaguchi T. S-1 in the treatment of pancreatic cancer. World J Gastroenterol 2014; 20(41): 15110-15118 |
| URL |
http://www.wjgnet.com/1007-9327/full/v20/i41/15110.htm |
| DOI |
http://dx.doi.org/10.3748/wjg.v20.i41.15110 |
All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.
